Accelerate Diagnostics, Inc. (AXDX) Director Buys $1,045,932.00 in Stock
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler acquired 51,600 shares of Accelerate Diagnostics stock in a transaction on Wednesday, October 11th. The shares were bought at an average price of $20.27 per share, for a total transaction of $1,045,932.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.01). Accelerate Diagnostics had a negative net margin of 5,062.48% and a negative return on equity of 67.44%. The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.40 million.
ILLEGAL ACTIVITY NOTICE: “Accelerate Diagnostics, Inc. (AXDX) Director Buys $1,045,932.00 in Stock” was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/13/accelerate-diagnostics-inc-axdx-director-buys-1045932-00-in-stock.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of Accelerate Diagnostics by 6.7% in the second quarter. Vanguard Group Inc. now owns 1,237,174 shares of the medical research company’s stock valued at $33,837,000 after buying an additional 77,753 shares during the period. Blair William & Co. IL lifted its stake in shares of Accelerate Diagnostics by 15.1% in the second quarter. Blair William & Co. IL now owns 787,483 shares of the medical research company’s stock valued at $21,538,000 after buying an additional 103,276 shares during the period. Nuveen Asset Management LLC lifted its stake in shares of Accelerate Diagnostics by 1.3% in the first quarter. Nuveen Asset Management LLC now owns 736,997 shares of the medical research company’s stock valued at $17,835,000 after buying an additional 9,568 shares during the period. State Street Corp lifted its stake in shares of Accelerate Diagnostics by 12.5% in the second quarter. State Street Corp now owns 475,078 shares of the medical research company’s stock valued at $12,993,000 after buying an additional 52,817 shares during the period. Finally, FMR LLC lifted its stake in shares of Accelerate Diagnostics by 40.0% in the second quarter. FMR LLC now owns 420,072 shares of the medical research company’s stock valued at $11,489,000 after buying an additional 120,072 shares during the period. Institutional investors and hedge funds own 44.43% of the company’s stock.
A number of brokerages have commented on AXDX. BidaskClub upgraded Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. BTIG Research restated a “buy” rating and set a $34.00 price objective on shares of Accelerate Diagnostics in a research note on Wednesday, July 12th. Zacks Investment Research cut Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Finally, ValuEngine cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Three investment analysts have rated the stock with a sell rating and two have issued a buy rating to the stock. Accelerate Diagnostics currently has an average rating of “Hold” and an average price target of $33.00.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.